Viatris is first to receive fda approval of generic restasis® (cyclosporine ophthalmic emulsion 0.05%) to treat dry eye disease

Pittsburgh, feb. 3, 2022 /prnewswire/ -- viatris inc. (nasdaq: vtrs) today announced that its subsidiary, mylan pharmaceuticals inc., has received approval from the u.s. food and drug administration (fda) for its abbreviated new drug application (anda) for cyclosporine ophthalmic emulsion 0.05%, the first generic version of allergan's restasis®. there are no remaining legal or regulatory barriers, and the company is launching immediately.
VTRS Ratings Summary
VTRS Quant Ranking